2019
Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS
Vocat C, Dunand M, Hubers SA, Bourdillon N, Millet G, Brown NJ, Wuerzner G, Grouzmann E, Eugster PJ. Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS. Analytical Chemistry 2019, 92: 859-866. PMID: 31790196, PMCID: PMC8541045, DOI: 10.1021/acs.analchem.9b03505.Peer-Reviewed Original ResearchConceptsNeuropeptide YNPY3-36Hypertensive patientsHealthy volunteersConcentrations of NPYEndogenous neuropeptide YHuman plasmaNPY2-36Pathological processesReference intervalsEndogenous peptidesChromatography-tandem mass spectrometryPatientsAcid peptideMS/MSVolunteersMetabolitesInter-assay precisionPeptidesPrototype peptideTandem mass spectrometryDistinct effectsOrthostasisCatecholaminesSubpicomolar concentrations
2010
Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro
Adam A, Montpas N, Keire D, Désormeaux A, Brown NJ, Marceau F, Westenberger B. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 2010, 31: 5741-5748. PMID: 20427081, PMCID: PMC2896062, DOI: 10.1016/j.biomaterials.2010.03.074.Peer-Reviewed Original ResearchConceptsContact system activationAnaphylactoid reactionsOversulfated chondroitin sulfateSystem activationSevere anaphylactoid reactionPlasma contact systemHuman plasmaInflammatory peptidesChondroitin sulfateEnzyme inhibitorsBK releaseDrug AdministrationBradykininHeparinSignificant correlationDefinitive evidenceDextran sulfatePlasma dilutionActivationConclusionPatientsPathophysiologyKininsAdministrationPlasma